US5114928A - Phospholipid-containing composition, a process for its preparation and its use as an excipient for pharmaceutical substances - Google Patents

Phospholipid-containing composition, a process for its preparation and its use as an excipient for pharmaceutical substances Download PDF

Info

Publication number
US5114928A
US5114928A US07/499,524 US49952490A US5114928A US 5114928 A US5114928 A US 5114928A US 49952490 A US49952490 A US 49952490A US 5114928 A US5114928 A US 5114928A
Authority
US
United States
Prior art keywords
phospholipid
lecithin
sugar
palatinit
containing composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/499,524
Other languages
English (en)
Inventor
Benedikt Gajdos
Heinz J. Mentzen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A NATTERMANN & CIE NATTERMANNALLEE 1 5000 KOLN 30 FED REP OF GERMANY A CORP OF FED REP OF GERMANY GmbH
A Natterman und Cie GmbH
Original Assignee
A Natterman und Cie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Natterman und Cie GmbH filed Critical A Natterman und Cie GmbH
Assigned to A. NATTERMANN & CIE. GMBH, NATTERMANNALLEE 1, 5000 KOLN 30, FED. REP. OF GERMANY, A CORP. OF THE FED. REP. OF GERMANY reassignment A. NATTERMANN & CIE. GMBH, NATTERMANNALLEE 1, 5000 KOLN 30, FED. REP. OF GERMANY, A CORP. OF THE FED. REP. OF GERMANY ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: GAJDOS, BENEDIKT, MENTZEN, HEINZ J.
Application granted granted Critical
Publication of US5114928A publication Critical patent/US5114928A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00Phosphatide compositions for foodstuffs, e.g. lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Definitions

  • the invention relates to new phospholipid-containing compositions which, in addition to the corresponding phospholipids, contain Palatinit as a solidifying agent and if appropriate one or more auxiliaries, and a process for their preparation.
  • the composition can be used as a solid oral presentation form.
  • Phospholipids occur widely in nature and can be obtained from animal and vegetable materials.
  • the main sources are eggs (egg lecithin) and soya (soya lecithin), oil seeds and oil fruits, such as, for example, coconutcopra, palm kernels, groundnuts, rape, sunflower kernels, oil palms and olives.
  • the phospholipids are predominantly obtained as a by-product in the production of vegetable oils.
  • a viscous mass is obtained by the so-called desliming of the vegetable oils, which is effected by passing small amounts of steam or water into the crude oil at elevated temperatures.
  • This so-called lecithin slime has a varying composition, depending on its origin:
  • the commercially available crude lecithin is obtained by drying the lecithin slime in an evaporator at elevated temperatures (80° C.) over a relatively long period of time (from 6-12 hours) or at 100° C. in a thin film evaporator with a shorter residence time.
  • soya lecithin which, after drying, contains about 52% by weight of phospholipids, 35% by weight of oils and fatty acids, 10% by weight of glycolipids and sugars, 2% by weight of non-hydrolysable portions and 1% by weight of water.
  • de-oiled phospholipids or de-oiled crude lecithin which contains only small amounts of oil and other concomitant lipids
  • solvents for example acetone.
  • the lecithin fractions obtained have varying phospholipid compositions depending on their origin:
  • the individual lecithins can also be purified by known processes and the corresponding phospholipids can be separated into the individual constituents, such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, phosphatidylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylserine or lysophosphatidylglycerol, or olefinic mixtures can be prepared.
  • the phospholipid mixtures of very different composition starting from wet lecithin slime, crude lecithin and de-oiled lecithin up to phospholipid mixtures of defined composition or even pure phospholipids, such as, for example, phosphatidylcholine, have physical properties which deviate very widely from one another.
  • the phospholipid mixtures have a very different consistency from liquid to viscous-plastic.
  • the plasticity of the lecithin increases with its degree of purity, that is to say as the phosphatidylcholine content increases and the oil content decreases.
  • lecithin and, to an increasing degree, highly pure lecithin are available, as is known, as a very highly viscous, paste-like composition, working already presents considerable difficulties because of the viscosity of the lecithin.
  • the lecithin is difficult to meter, and because of its viscous consistency remains stuck to the equipment with which it comes into contact, so that the residues which remain require frequent and expensive cleaning of the equipment.
  • U.S. Pat. No. 2,057,695 describes a process for the preparation of powdered oil-free phosphatide products which have a very high lecithin content in the end product.
  • crude phosphatide is de-oiled by extraction several times with acetone, water is added to the oil-free product, the residue of undissolved material is removed and the aqueous phosphatide emulsion which remains is further dried by spray drying or roller drying. Additions of sugar may be made here.
  • the oil-free aqueous lecithin solution which has a very high water content (about 20 to 50 times the amount), is then mixed directly with a stabilizer, such as, for example, salicylic acid, and can then subsequently be dried. If sugar is added, for example sucrose, a phospholipid content of a maximum of 60% can be achieved.
  • U.S. Pat. No. 3,012,888 describes oil-free phosphatide products which contain 1-5% of monosaccharide and are obtained by adding a 40% strength solution of corresponding monosaccharide to crude lecithin, heating the mixture to 60°-70° C. until a homogeneous mass is obtained, subsequently drying the mass in vacuo and removing the oil with acetone. Finally, the residue solution is removed in vacuo.
  • the aim of the application is the preparation of storage-stable phosphatide products starting from aqueous solution systems. If non-reducing sugars are used, no satisfactory results are obtained.
  • DE-PS 642,932 describes an industrial process for drying lecithin and subsequent coating with wax-like substances, whereas in DE-PS 973,741, drying by comminution under the influence of heat takes place, after de-oiling with acetone.
  • DE-PS 508,353 (U.S. Pat. No. 1,776,721) contains technical instructions for mixing lecithin with flour or flour products.
  • U.S. Pat. No. 1,988,050 describes a mixture of phospholipids crude (lecithin) and cereal germ which is de-oiled or dried with alcohol.
  • fatty acid esters are added to the lecithin.
  • U.S. Pat. No. 2,447,726 describes mixing of lecithin with gelose, a reducing sugar obtained form "Irish moss", and U.S. Pat. No. 2,708,631 describes a solution of a maximum of 20% of lecithin in dextrose.
  • U.S. Pat. No. 2,973,381 describes a composition of phospholipid and tocopherol (vitamin E) whereas in U.S. Pat. No. 3,480,544 phospholipids and SiO 2 are mixed with one another.
  • the aim of the present invention is therefore to discover an additive and a method with which phospholipid mixtures from different starting substances are converted into products which can also have a high phosphatidylcholine content and the consistency of which can be controlled by the choice of additive and its amount.
  • a phospholipid-containing composition which contains sugar as a solidifying agent and customary auxiliaries, characterized in that a 1:1 mixture of glucopyranosido-1,6-mannitol and glucopyranosido-1,6-sorbitol (PALATINIT) in a weight ratio of phospholipid:PALATINIT of 1:20 to 20:1 is present as the sugar.
  • a 1:1 mixture of glucopyranosido-1,6-mannitol and glucopyranosido-1,6-sorbitol (PALATINIT) in a weight ratio of phospholipid:PALATINIT of 1:20 to 20:1 is present as the sugar.
  • PALATINIT and lecithin can be mixed with one another directly, without the customary antiadhesives, and the sticky properties of the lecithin and its strong hygroscopic character, which is otherwise a great hindrance to effective processing, can be neutralized completely by means of the PALATINIT, so that solid stable products which are very easy to handle are formed in a one-stage process.
  • the consistency of the product can be controlled here from pasty to very solid via the ratio of PALATINIT to phospholipid.
  • the weight ratio of phospholipids:PALATINIT is 1:20 to 20:1, preferably 4:1 to 20:1.
  • PALATINIT is a non-reducing sugar and the tradename for a hydrogenated isomaltulose which consists of a 1:1 mixture of glucopyranosido-1,6-mannitol and glucopyranosido-1,6-sorbitol and has a purity of >99% (J. S. Hoeven, Caries Res., 13 (1979), page 301).
  • composition can contain naturally occurring or synthetic phospholipids.
  • the phospholipid content can vary from 5 to 98%, such as, for example, egg lecithin (about 80% of phosphatidylcholine, the remainder being other phospholipids), soya lecithin (about 77% of phospholipids, 13% of phytoglycolipids, 2% of phosphatidyl acid and 8% of concomitant lipids) or highly pure phospholipids having a phosphatidylcholine content of up to 96%, can be employed as the phospholipid-containing starting mixtures.
  • Phospholipid mixtures of different composition can likewise also be employed.
  • the phospholipid fractions can be obtained from soya beans, rape, sunflower kernels and other oil fruits and oil seeds, but preferably from soya beans, by processes which are known per se in accordance with DE-OS 30 47 048, DE-OS 30 47 012 and DE-OS 30 47 011.
  • customary aroma substances such as, for example, vanillin, aniseed, caramel, chocolate, malt, peppermint oil or fruit aromas, such as, for example, banana, orange, raspberry or mixtures thereof.
  • Sweeteners for example sodium cyclamate, saccharin, xylitol, cane sugar (sucrose), glucose, fructose or maltose or other sweetener derivatives, can likewise also be used. It is also possible to combine several of the abovementioned auxiliaries, in order thus to be able to prepare the composition of desired taste.
  • the amount of auxiliaries in the composition can be up to 5% by weight, based on the total weight.
  • the products can be processed by customary methods into grains, granules, bars, chewable tablets and the like, or converted into other forms which allow further processing without problems.
  • the mixture of lecithin or phospholipid/PALATINIT can be prepared by producing a lecithin solution, mixing this with the corresponding amount of PALATINIT or PALATINIT solution and subsequently freeing the mixture from adhering solvent in a roll mill drier or spray drier.
  • composition by adding a melt of PALATINIT to lecithin or phospholipids under the influence of heat and mixing the components by customary methods until a homogeneous mass has formed.
  • customary aroma substances such as, for example, vanillin, aniseed, caramel, chocolate, malt, peppermint oil or fruit aromas, such as, for example, banana, orange, raspberry or mixtures thereof, can then be added to this homogeneous phase.
  • sweeteners for example sodium cyclamate, saccharin, xylitol, cane sugar (sucrose), glucose, fructose or other sweetener derivatives or corresponding combinations.
  • the entire mass After its homogenization, the entire mass can be shaped under plastic conditions under the influence of heat or, after cooling, processed to grains, granules, bars, tablets and the like, or converted into other forms which allow further processing without problems.
  • the composition is plastic at temperatures from 50° C. to 80° C., so that it is preferable to prepare the composition at these temperatures by mixing the constituents, and also to convert it into oral presentation forms.
  • the composition is preferably used as an oral presentation form. It can in this way also serve as an excipient for medicaments for oral administration, that is to say pharmaceutically active substances.
  • Oral presentation forms are, for example, granules, tablets, chewable tablets, bars/toffees, film-coated tablets and filled hard gelatin capsules.
  • the purified soya lecithin is kneaded at 80° C. in the customary manner and the hot PALATINIT mass at 140° C. is added.
  • vanillin is added and the mixture is kneaded until a homogeneous mass has formed.
  • the product can be shaped under plastic conditions under the influence of heat or, after cooling, processed to grains, granules, bars, chewable tablets and the like, it also being possible to incorporate pharmaceutically active substances, if appropriate, so that the composition is used as an excipient.
  • a solid product is formed.
  • a solid product is formed.
  • a solid product is formed.
  • a mass which has very viscous, pasty properties but is not sticky is formed.
  • a solid product is formed.
  • a solid product is formed.
  • a solid product is formed.
  • a product which has a very viscous, pasty consistency but is not sticky is formed.
  • the product has the same properties as in Example 9.
  • the finished solid product from Example 2 is ground to free-flowing granules by customary processes and the granules are then mixed with the PALATINIT powder and the SiO 2 .
  • Chewable tablets having a diameter of 16 mm (weight 1.5 g) and those having a diameter of 22 mm (weight 2.5 g) are pressed in a customary tablet press.
  • a soya lecithin of the following composition was used: 35% of phosphatidylcholine, 26-33% of other phospholipids and other concomitant substances and 32-39% of oil.
  • the substances are mixed together and pressed to biplanar chewable tablets having a diameter of 25 mm and a weight of 2.86 g with the aid of a tablet press.
  • This entire mixture is then pressed to biplanar chewable tablets having a diameter of 25 mm and a weight of 3.0 g with the aid of a tablet press.
  • the base is mixed with the Alugel granules and other substances and the mixture is then pressed to chewable tablets weighing 2.5 g.
  • Tabletting experiments were carried out with granules which contained lecithin carbohydrate and have been obtained by mixing the solid starting substances.
  • the granules were obtained by means of a AMK kneader or Berstorff extruder. After mixing the granules with the auxiliaries listed, the tablets were pressed in a biplanar stamp form of 25 mm diameter in a tablet press of the type Hillian RT 116.
  • Capping of the tablets means that these disintegrate into two flat (cap) halves on leaving the pressing die. A yes in this column leads to a devaluation of the properties.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US07/499,524 1988-08-09 1989-08-01 Phospholipid-containing composition, a process for its preparation and its use as an excipient for pharmaceutical substances Expired - Lifetime US5114928A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3826946A DE3826946C1 (zh) 1988-08-09 1988-08-09
DE3826946 1988-08-09

Publications (1)

Publication Number Publication Date
US5114928A true US5114928A (en) 1992-05-19

Family

ID=6360482

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/499,524 Expired - Lifetime US5114928A (en) 1988-08-09 1989-08-01 Phospholipid-containing composition, a process for its preparation and its use as an excipient for pharmaceutical substances

Country Status (10)

Country Link
US (1) US5114928A (zh)
EP (2) EP0428582B1 (zh)
JP (1) JPH02504397A (zh)
KR (1) KR930003882B1 (zh)
CN (1) CN1037149C (zh)
CA (1) CA1336957C (zh)
DE (2) DE3826946C1 (zh)
ES (1) ES2043117T3 (zh)
GR (1) GR3004892T3 (zh)
WO (1) WO1990001269A1 (zh)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5186940A (en) * 1985-10-18 1993-02-16 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5585109A (en) * 1993-03-24 1996-12-17 Hayward; James A. Cosmetic delivery system for salicylic acid and process for preparation of same
AU750373B2 (en) * 1998-04-28 2002-07-18 Sudzucker Aktiengesellschaft Therapeutic anti-cold agent containing isomalt as an active ingredient
WO2005048731A2 (en) * 2003-11-17 2005-06-02 Cargill, Incorporated Lecithin-containing granular compositions and methods of their preparation
US7297344B1 (en) 1999-05-27 2007-11-20 Euro-Celtique, S.A. Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
US7300667B1 (en) 1999-05-27 2007-11-27 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
US20080038330A1 (en) * 1998-05-27 2008-02-14 Euro-Celtique S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds of the lower respiratory tract
US7468194B1 (en) 1999-05-27 2008-12-23 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory agents
US20130059036A1 (en) * 2010-03-12 2013-03-07 Dupont Nutrition Biosciences Aps Process
US20140072617A1 (en) * 2007-09-26 2014-03-13 Lvmh Recherche Method for preventing or slowing down the appearance of the effects of skin ageing using a tocopheryl phosphate in liposomes
US10117885B2 (en) * 2011-08-11 2018-11-06 Allergy Research Group, Llc Chewable lipid supplements for treating pain and fibromyalgia
US11253531B2 (en) 2011-08-11 2022-02-22 Nutritional Therapeutics, Inc. Lipid supplements for reducing nerve action potentials

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971798A (en) * 1989-11-30 1990-11-20 Miles Inc. Hard confections containing hydrogenated isomaltulose and medicinally active ingredient
DE69429611D1 (de) * 1993-10-29 2002-02-14 Dsm Nv Backverbesserende Zusammensetzungen
DE19536394A1 (de) * 1995-09-29 1997-04-03 Basf Ag Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze
DE19629167C2 (de) 1996-07-19 2000-05-04 Einhorn Apotheke Dr Guenther H Feste orale, antikariogene Zusammensetzung in Form einer Lutschtablette zum Reinigen der Mundhöhle und Zähne
US6312703B1 (en) * 1998-02-06 2001-11-06 Lecigel, Llc Compressed lecithin preparations
GB9828013D0 (en) * 1998-12-18 1999-02-10 Lovesgrove Res Ltd Specific phospholipid-lipid mixtures for inclusion in animal feed
AU5428800A (en) * 1999-06-29 2001-01-31 Takeda Chemical Industries Ltd. Tablets quickly disintegrating in mouth
DE10340741A1 (de) * 2003-09-04 2005-03-31 Degussa Food Ingredients Gmbh Formulierung auf Phospholipidbasis
EP1738755B1 (en) * 2004-04-14 2018-05-30 Kyowa Hakko Bio Co., Ltd. Tablet containing branched chain amino acid and process for producing the same
CN1305881C (zh) * 2004-08-13 2007-03-21 河南工业大学 磷脂酰胆碱的制备方法
US8535750B2 (en) 2005-05-17 2013-09-17 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
CN102946866A (zh) * 2010-05-14 2013-02-27 阿彻丹尼尔斯米德兰德公司 包含有机凝胶的食品组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3012888A (en) * 1959-04-13 1961-12-12 Central Soya Co Method for preparing a granular oilfree phosphatide product
EP0072469A2 (en) * 1981-08-18 1983-02-23 Richard Hochschild Method for making a pharmaceutical and/or nutritional dosage form

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2057695A (en) * 1933-12-13 1936-10-20 American Lecithin Co Method for the production of vegetable phosphatide preparations
US2447726A (en) * 1945-09-21 1948-08-24 Wilber J Allingham Lecithin composition
US2430553A (en) * 1946-11-02 1947-11-11 Frank E Bigelow Lecithinated sugar
US2708631A (en) * 1952-10-21 1955-05-17 Sadie Neiman Lecithin composition and method of producing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3012888A (en) * 1959-04-13 1961-12-12 Central Soya Co Method for preparing a granular oilfree phosphatide product
EP0072469A2 (en) * 1981-08-18 1983-02-23 Richard Hochschild Method for making a pharmaceutical and/or nutritional dosage form

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, vol. 104, No. 10, Abstract 74837r, Mar. 10, 1986. *
Chemical Abstracts, vol. 109, No. 19, Abstract 169028v, Nov. 7, 1988. *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5186940A (en) * 1985-10-18 1993-02-16 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5585109A (en) * 1993-03-24 1996-12-17 Hayward; James A. Cosmetic delivery system for salicylic acid and process for preparation of same
AU750373B2 (en) * 1998-04-28 2002-07-18 Sudzucker Aktiengesellschaft Therapeutic anti-cold agent containing isomalt as an active ingredient
US20080038330A1 (en) * 1998-05-27 2008-02-14 Euro-Celtique S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds of the lower respiratory tract
US7468194B1 (en) 1999-05-27 2008-12-23 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory agents
US7297344B1 (en) 1999-05-27 2007-11-20 Euro-Celtique, S.A. Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
US7300667B1 (en) 1999-05-27 2007-11-27 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
US20050214369A1 (en) * 2003-11-17 2005-09-29 Ko Myong K Lecithin-containing granular compositions and methods of their preparation
WO2005048731A3 (en) * 2003-11-17 2005-09-15 Cargill Inc Lecithin-containing granular compositions and methods of their preparation
WO2005048731A2 (en) * 2003-11-17 2005-06-02 Cargill, Incorporated Lecithin-containing granular compositions and methods of their preparation
US20140072617A1 (en) * 2007-09-26 2014-03-13 Lvmh Recherche Method for preventing or slowing down the appearance of the effects of skin ageing using a tocopheryl phosphate in liposomes
US20130059036A1 (en) * 2010-03-12 2013-03-07 Dupont Nutrition Biosciences Aps Process
US10117885B2 (en) * 2011-08-11 2018-11-06 Allergy Research Group, Llc Chewable lipid supplements for treating pain and fibromyalgia
US10874681B2 (en) 2011-08-11 2020-12-29 Nutritional Therapeutics, Inc. Oral lipid supplements for treating pain and fibromyalgia
US11253531B2 (en) 2011-08-11 2022-02-22 Nutritional Therapeutics, Inc. Lipid supplements for reducing nerve action potentials

Also Published As

Publication number Publication date
DE68901771T2 (de) 1992-12-17
DE3826946C1 (zh) 1990-03-15
EP0428582B1 (en) 1992-06-10
GR3004892T3 (zh) 1993-04-28
CN1037149C (zh) 1998-01-28
ES2043117T3 (es) 1993-12-16
KR930003882B1 (ko) 1993-05-15
EP0354442A1 (en) 1990-02-14
CN1040144A (zh) 1990-03-07
EP0428582A1 (en) 1991-05-29
JPH02504397A (ja) 1990-12-13
JPH0571596B2 (zh) 1993-10-07
DE68901771D1 (de) 1992-07-16
KR900701174A (ko) 1990-12-01
CA1336957C (en) 1995-09-12
WO1990001269A1 (en) 1990-02-22

Similar Documents

Publication Publication Date Title
US5114928A (en) Phospholipid-containing composition, a process for its preparation and its use as an excipient for pharmaceutical substances
KR100258223B1 (ko) 신속 용해형 정제 및 그의 제조법
EP0847242B1 (de) Zuckerfreie dragierte produkte
CA2044043C (en) Process for the production of rapidly disintegrating sheet-like presentations
EP1163901B1 (en) Chewable soft capsules having improved administration properties and process for producing the same
US4786502A (en) Palatable solid pharmaceutical compositions
EP1008343A1 (en) Rapidly soluble filmy preparation
US4013775A (en) Process for preparing a sugar tablet
FI96095C (fi) Menetelmä jatkuvavapautteisen lääkevalmisteen valmistamiseksi
HU196305B (en) Process for production of bubbling bimixture with acid-fastening effect and bubbling tablet containing as active substance histamin-h-below 2 antagonist
JPH0818974B2 (ja) 薬用吸着質及びその製法
DE69815856T2 (de) Cefadroxilmonohydrat tablettenformulierung
EP0265226B1 (en) Spray dried acetaminophen
KR101409302B1 (ko) 인도메타신 및/또는 아세메타신을 포함하는 약학적 조성물
EP3225256B1 (en) Disintegrative particle composition including pulverized lactose or granulated lactose
RU2222224C2 (ru) Сырье для прессованного продукта, пригодное для прямого прессования
US4670251A (en) Microcrystalline tableting excipient derived from whey
GB2195891A (en) Improving palatability of pharmaceutical chewable tablets
EP0636023B1 (en) Aminoguanidine spray drying process
JP3995202B2 (ja) 経口用ウコン類組成物
JPH09316006A (ja) 口腔内溶解性固形製剤
JP3290429B2 (ja) 服用性を改良した咀嚼型ソフトカプセル剤およびその製法
RU2761828C2 (ru) Фармацевтическая композиция, содержащая бензокаин с усиленной стабильностью
RU2363469C2 (ru) Состав для капсул
JPH07106981B2 (ja) 安定な経口用アズレンスルホン酸ナトリウム製剤

Legal Events

Date Code Title Description
AS Assignment

Owner name: A. NATTERMANN & CIE. GMBH, NATTERMANNALLEE 1, 5000

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:GAJDOS, BENEDIKT;MENTZEN, HEINZ J.;REEL/FRAME:005684/0029

Effective date: 19900516

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 12

SULP Surcharge for late payment

Year of fee payment: 11